243 related articles for article (PubMed ID: 12900280)
1. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.
Sette A; Fikes J
Curr Opin Immunol; 2003 Aug; 15(4):461-70. PubMed ID: 12900280
[TBL] [Abstract][Full Text] [Related]
2. [Current status and strategy of research on epitope-based vaccine].
Chen Y; Dai C
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Sep; 33(5):315-6. PubMed ID: 15376374
[No Abstract] [Full Text] [Related]
3. CD4+ T cell epitope discovery and rational vaccine design.
Rosa DS; Ribeiro SP; Cunha-Neto E
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):121-30. PubMed ID: 20155490
[TBL] [Abstract][Full Text] [Related]
4. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.
Liu J; Ewald BA; Lynch DM; Nanda A; Sumida SM; Barouch DH
J Virol; 2006 Dec; 80(24):11991-7. PubMed ID: 17005652
[TBL] [Abstract][Full Text] [Related]
5. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
7. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
[TBL] [Abstract][Full Text] [Related]
8. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
9. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope.
el-Shami K; Tirosh B; Bar-Haim E; Carmon L; Vadai E; Fridkin M; Feldman M; Eisenbach L
Eur J Immunol; 1999 Oct; 29(10):3295-301. PubMed ID: 10540341
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in epitope design for immunotherapy of cancer.
Chiarella P; Massi E; De Robertis M; Fazio VM; Signori E
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):227-40. PubMed ID: 19522699
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
12. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon.
Rodriguez F; Harkins S; Slifka MK; Whitton JL
J Virol; 2002 May; 76(9):4251-9. PubMed ID: 11932390
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
[TBL] [Abstract][Full Text] [Related]
14. The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice.
Reiser M; Wieland A; Plachter B; Mertens T; Greiner J; Schirmbeck R
J Immunol; 2011 Sep; 187(5):2172-80. PubMed ID: 21810614
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic evaluation of FMD virus immuno-dominant epitopes coupled with IL-2/FcIgG in BALB/c mice.
Doosti M; Nassiri M; Nasiri K; Tahmoorespur M; Zibaee S
Microb Pathog; 2019 Jul; 132():30-37. PubMed ID: 31004723
[TBL] [Abstract][Full Text] [Related]
16. Computer-aided design of T-cell epitope-based vaccines: addressing population coverage.
Oyarzun P; Kobe B
Int J Immunogenet; 2015 Oct; 42(5):313-21. PubMed ID: 26211755
[TBL] [Abstract][Full Text] [Related]
17. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
18. Immunodominance: intermolecular competition between MHC class II molecules by covalently linked T cell epitopes.
Wang Y; Smith JA; Gefter ML; Perkins DL
J Immunol; 1992 May; 148(10):3034-41. PubMed ID: 1578129
[TBL] [Abstract][Full Text] [Related]
19. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
[TBL] [Abstract][Full Text] [Related]
20. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.
Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K
Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
